Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

12 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
8(47.1%)
Phase 3
4(23.5%)
Phase 1
3(17.6%)
Phase 2
2(11.8%)
17Total
Phase 4(8)
Phase 3(4)
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT05262010Phase 3Recruiting

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Role: collaborator

NCT07272434Phase 3Recruiting

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Role: collaborator

NCT05204589Phase 3Completed

Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Role: collaborator

NCT06043388Phase 1Unknown

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

Role: collaborator

NCT05352867Phase 2Completed

Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People

Role: collaborator

NCT05374954Phase 3Unknown

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above

Role: collaborator

NCT05890521Phase 4Unknown

Safety Study of COVID19 Vaccine on the Market

Role: collaborator

NCT05602480Phase 1Unknown

Phase I Clinical Trial of a Candidate PCV13 in Healthy People

Role: collaborator

NCT05480436Phase 4Unknown

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Role: collaborator

NCT04559204Phase 4Completed

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

Role: collaborator

NCT05065879Phase 4Completed

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05104437Phase 4Unknown

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05104333Phase 4Unknown

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05065892Phase 4Unknown

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Role: collaborator

NCT05003466Phase 2Unknown

Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)

Role: collaborator

NCT05003479Phase 1Unknown

Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)

Role: collaborator

NCT03519568Phase 4Unknown

Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine

Role: collaborator

All 17 trials loaded